Home » Blogs » BioWorld Perspectives » Crowdfunding's slow march

BioWorld Perspectives
RSS

BioWorld

Crowdfunding's slow march

Jan. 29, 2015

By Michael Fitzhugh

No Comments

You must login or register in order to post a comment.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 30, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 30, 2024.
Corbus rockets on early clinical data for next-gen Nectin-4 ADC candidate
BioWorld
Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a...
Following JPM, 2024 outlook ranges from hopeful to cautious
BioWorld
Setting the tone for the biopharma industry as it enters a new year, the J.P. Morgan Healthcare Conference (JPM) held each January has once again led to...
Tempest Therapeutics presents new TREX1 inhibitors for cancer
BioWorld Science
Tempest Therapeutics Inc. has divulged three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe

BioWorld Perspectives RSS

Crowdfunding's slow march

Report Abusive Comment

BioWorld Perspectives
RSS